首页> 外文OA文献 >Co-occurring KRAS mutation/LKB1 loss in non-small cell lung cancer cells results in enhanced metabolic activity susceptible to caloric restriction: an in vitro integrated multilevel approach
【2h】

Co-occurring KRAS mutation/LKB1 loss in non-small cell lung cancer cells results in enhanced metabolic activity susceptible to caloric restriction: an in vitro integrated multilevel approach

机译:非小细胞肺癌细胞的共同发生的KRA突变/ LKB1损失导致增强的代谢活性易受热限制:一种体外集成多级方法

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Abstract Background Non–small-cell lung cancer (NSCLC) is a heterogeneous disease, with multiple different oncogenic mutations. Approximately 25–30% of NSCLC patients present KRAS mutations, which confer poor prognosis and high risk of tumor recurrence. About half of NSCLCs with activating KRAS lesions also have deletions or inactivating mutations in the serine/threonine kinase 11 (LKB1) gene. Loss of LKB1 on a KRAS-mutant background may represent a significant source of heterogeneity contributing to poor response to therapy. Methods Here, we employed an integrated multilevel proteomics, metabolomics and functional in-vitro approach in NSCLC H1299 isogenic cells to define their metabolic state associated with the presence of different genetic background. Protein levels were obtained by label free and single reaction monitoring (SRM)-based proteomics. The metabolic state was studied coupling targeted and untargeted mass spectrometry (MS) strategy. In vitro metabolic dependencies were evaluated using 2-deoxy glucose (2-DG) treatment or glucose/glutamine nutrient limitation. Results Here we demonstrate that co-occurring KRAS mutation/LKB1 loss in NSCLC cells allowed efficient exploitation of glycolysis and oxidative phosphorylation, when compared to cells with each single oncologic genotype. The enhanced metabolic activity rendered the viability of cells with both genetic lesions susceptible towards nutrient limitation. Conclusions Co-occurrence of KRAS mutation and LKB1 loss in NSCLC cells induced an enhanced metabolic activity mirrored by a growth rate vulnerability under limited nutrient conditions relative to cells with the single oncogenetic lesions. Our results hint at the possibility that energy stress induced by calorie restriction regimens may sensitize NSCLCs with these co-occurring lesions to cytotoxic chemotherapy.
机译:摘要背景非小细胞肺癌(NSCLC)是一种异质疾病,具有多种不同的致癌突变。大约25-30%的NSCLC患者呈现KRAS突变,其预后差和肿瘤复发的高风险。具有激活KRA病变的大约一半的NSCLC也具有丝氨酸/苏氨酸激酶11(LKB1)基因中的缺失或灭活突变。 KRAS-突变体背景上的LKB1的丧失可以代表有助于对治疗的不良反应的重要来源。方法在此,我们在NSCLC H1299中源细胞中使用了一种集成的多级蛋白质组学,代谢组合和功能性在体外方法,以定义与不同遗传背景的存在相关的它们的代谢状态。通过标记和基于单反应监测(SRM)的蛋白质组学获得蛋白质水平。研究了代谢状态,研究了靶向和未确定的质谱(MS)策略。使用2-脱氧葡萄糖(2-DG)处理或葡萄糖/谷氨酰胺营养限制来评估体外代谢依赖性。结果,我们证明,与每种肿瘤学基因型的细胞相比,NSCLC细胞中的共同克拉斯突变/ LKB1损失允许有效利用糖酵解和氧化磷酸化。增强的代谢活性呈现细胞的活力与两个遗传病变朝营养限制敏感。结论NSCLC细胞中KRAS突变和LKB1损失的共同发生诱导通过相对于具有单一致癌病变的细胞的有限营养条件下的生长速度脆弱性镜像增强的代谢活性。我们的结果暗示了卡路里限制方案诱导的能量应力可能使NSCLC与这些共同发生的病变敏感到细胞毒性化疗。

著录项

相似文献

  • 外文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号